Breaking Finance News

A report released earlier today by Chardan Capital about Medical Transcription Billing (NASDAQ:MTBC) raises the target price to $2.75

Yesterday Medical Transcription Billing (NASDAQ:MTBC) traded 9.34% higher at $3.16. The company’s 50-day moving average is $2.38 and its 200-day moving average is $1.73. The last stock close price is up 82.21% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 1,013,005 shares of the stock were exchanged, down from an average trading volume of 1,575,600

In a report released on 11/14/2017 Chardan Capital increased the stock price target of Medical Transcription Billing (NASDAQ:MTBC) from $2.25 to $2.75 indicating a possible downside of -0.13%.

See Chart Below

Medical Transcription Billing (NASDAQ:MTBC)

Medical Transcription Billing has a 52 week low of $0.29 and a 52 week high of $5.44 The company’s market cap is currently $0.

About Medical Transcription Billing (NASDAQ:MTBC)

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company's offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *